Blinded investigational medicinal product refers to investigational medication that is manufactured and packaged so that study participants, investigators, and other involved personnel cannot distinguish between the active treatment and placebo. This requires identical appearance, taste, smell, and texture, as well as identical packaging, across all treatment arms. The quality of blinding is critical to eliminating performance and ascertainment bias in controlled clinical trials.
Managing clinical supply with blinded medication presents complex logistical challenges. Suitable placebos must have identical physical properties, while active treatments may require taste or odor masking. Packaging systems must enable identical labeling while also supporting emergency unblinding procedures. Temperature-controlled storage and distribution require specialized cold-chain management.
Quality control for blinded investigational medicinal product includes comprehensive testing of appearance, dissolution, stability, and identity. Interactive voice/web response systems (IVRS/IWRS) manage medication assignment and tracking while maintaining blinding integrity. Emergency unblinding procedures must enable rapid access without jeopardizing overall study blinding.